Retinoic acid syndrome

Retinoic acid syndrome
Other names: Differentiation syndrome
SpecialtyOncology, hematology

Retinoic acid syndrome (RAS) is a potentially life-threatening complication observed in people with acute promyelocytic leukemia (APML) and first thought to be specifically associated with all-trans retinoic acid (ATRA) (also known as tretinoin) treatment.[1] Subsequently, so-called RAS was recognized in APML patients who had been treated with another highly efficacious drug, arsenic trioxide, and yet did not appear in patients treated with tretinoin for other disorders. These facts and others support the notion that RAS depends on the presence of the malignant promyelocytes. This has led to the growing deprecation of the term 'retinoic acid syndrome' and to an increasing use of the term differentiation syndrome to signify this APML treatment complication.[2]

Signs and symptoms

The syndrome is characterized by dyspnea, fever, weight gain, hypotension, and pulmonary infiltrates. This is effectively treated by giving dexamethasone and withholding ATRA (or arsenic trioxide) in severe cases. An elevated white count is sometimes associated with this syndrome, but is not always pathognomonic.

Once RAS has resolved, pro-differentiation chemotherapy can be resumed.

Causes

The cause of RAS is not clear. Several causes have been speculated, including a capillary leak syndrome from cytokine release from the differentiating myeloid cells. Alternatively, ATRA may cause the maturing myeloid cells to acquire the ability to infiltrate organs such as the lung.

Mediation by cathepsin G has been suggested.[3]

Diagnosis

X-ray in individual with differentiation syndrome showed mild cardiomegaly

The diagnosis of Retinoic acid syndrome is done via clinical features[4]

Treatment

The treatment of RAS usually involves administering dexamethasone IV, with the dosage usually 10 mg twice a day for 10 days. It is important for patients to discontinue the use of tretinoin due to the elevation of white blood cells and possible low blood oxygen.

See also

References

  1. ↑ Breccia M, Latagliata R, Carmosino I, et al. (December 2008). "Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin". Haematologica. 93 (12): 1918–20. doi:10.3324/haematol.13510. PMID 18945746.
  2. ↑ Weinberger, Steven. "Differentiation (retinoic acid) syndrome". Archived from the original on 7 May 2011. Retrieved 10 March 2011.
  3. ↑ Tallman MS (February 2002). "Retinoic acid syndrome: a problem of the past?". Leukemia. 16 (2): 160–1. doi:10.1038/sj.leu.2402344. PMID 11840279.
  4. ↑ Patatanian, E.; Thompson, D. F. (August 2008). "Retinoic acid syndrome: a review". Journal of Clinical Pharmacy and Therapeutics. 33 (4): 331–338. doi:10.1111/j.1365-2710.2008.00935.x. ISSN 1365-2710. Archived from the original on 2022-06-15. Retrieved 2023-11-20.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.